Akebia Therapeutics
AKBA
151 hedge funds and large institutions have $421M invested in Akebia Therapeutics in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 60 increasing their positions, 29 reducing their positions, and 37 closing their positions.
3,408% more call options, than puts
Call options by funds: $24.4M | Put options by funds: $695K
107% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 29
1.41% more ownership
Funds ownership: 72.35% → 73.76% (+1.4%)
11% less funds holding
Funds holding: 169 → 151 (-18)
38% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 37
39% less capital invested
Capital invested by funds: $694M → $421M (-$273M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.7M |
| 2 |
BlackRock
New York
|
+$9.93M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$9.27M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.24M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$14M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$11.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$9.35M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$4.95M |
| 5 |
SIM
Spark Investment Management
New York
|
-$4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Stifel Financial
St. Louis,
Missouri
| – | -$90K | -10,974 | Closed |
|
|
SCM
177
Stevens Capital Management
Radnor,
Pennsylvania
| – | -$89K | -10,837 | Closed |
|
178
SEI Investments
Oaks,
Pennsylvania
| – | -$67K | -8,661 | Closed |
|
|
MOACM
179
Mutual of America Capital Management
New York
| – | -$45K | -5,500 | Closed |
|
|
FQ
180
First Quadrant
Glendale,
California
| – | -$43K | -5,262 | Closed |
|
|
MCM
181
Manchester Capital Management
Manchester,
Vermont
| – | -$16K | -1,971 | Closed |
|
|
AF
182
Advisornet Financial
Minnetonka,
Minnesota
| – | -$8K | -975 | Closed |
|
|
TRCT
183
Tower Research Capital (TRC)
New York
| – | -$3K | -388 | Closed |
|
|
CAM
184
Cresset Asset Management
Chicago,
Illinois
| – | -$1K | -142 | Closed |
|
|
FANJ
185
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$1K | -104 | Closed |
|
|
VCM
186
Versant Capital Management
Phoenix,
Arizona
| – | +$330 | +58 | New |
|
AKBA Hedge Fund Activity: Q2 2019 in Review
151 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2019, worth a combined $421M — down 39% from $694M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of AKBA and 23 opened new positions — a net loss of 14 holders — while 29 trimmed existing stakes and 60 added.
The largest buyer was State Street, adding an estimated $13.7M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $14M sold.
- 151 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2019, down from 169 in Q1 2019.
- Funds reported $421M of Akebia Therapeutics stock for Q2 2019, down 39% quarter-over-quarter.
- 23 funds opened new Akebia Therapeutics positions in Q2 2019 and 37 closed out, a net change of -14 holders.
- The largest Akebia Therapeutics buyer in Q2 2019 was State Street, an estimated $13.7M added.
- The largest Akebia Therapeutics seller in Q2 2019 was Perceptive Advisors, an estimated $14M sold.
Based on aggregated 13F filings for Q2 2019.